Nabriva Therapeutics rises on pneumonia drug approval in Taiwan
08/09/2021 13:07
** Drugmaker's shares NBRV.O rise 5.6% to $1.14
** Says its partner, Sumitomo Pharmaceuticals (Suzhou), got
approval in Taiwan to market oral and intravenous formulations
of co's drug XENLETA to treat community-acquired pneumonia in
adults urn:newsml:reuters.com:*:nFWN2QA017
** Stock set to rise for the first time in three sessions
** Down 55% YTD as of last close
(Reporting by Susan Mathew)
((susan.mathew@thomsonreuters.com))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update